Jci_page_head_homepage_01 Jci_page_head_homepage_02
Hui-Fang Cheng, Jun-Ling Wang, Ming-Zhi Zhang, Yoichi Miyazaki, Iekuni Ichikawa, James A. McKanna, Raymond C. Harris
Published in Volume 103, Issue 7
J Clin Invest. 1999; 103(7):953–961 doi:10.1172/JCI5505
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

(a) The COX-2 inhibitor SC58236 reverses captopril-mediated increases in plasma renin. Plasma renin increased significantly in rats administered captopril (100 mg/kg body weight per day in drinking water) (n = 4; **P < 0.01 compared with control); captopril-induced increased plasma renin activity was significantly inhibited by SC58236 (n = 4; *P < 0.01 compared with captopril group). (b) SC58236 reverses captopril-induced increases in renal renin activity. Renal renin activity increased significantly in rats administered captopril (n = 4; **P < 0.01), which was significantly inhibited by SC58236 (n = 4; *P < 0.05 compared with captopril group). (c) SC58236 reverses captopril-induced increases in renal renin mRNA expression. Renal renin mRNA increased significantly in rats administered captopril (n = 4; **P < 0.05), which was significantly inhibited by SC58236 (n = 4; *P < 0.05, compared with captopril group). Inset shows a representative experiment: 1, control; 2, captopril; 3, captopril + SC58236.